Naldemedine for Opioid-Induced Constipation in Patients With Cancer: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.

Scott Murray Takahiro Higashibata Takaomi Kessoku Shinya Kajiura Mami Hirakawa Shunsuke OyamadaKeisuke AriyoshiTakeshi Yamada Yoshiyuki YamamotoYasuyuki TakashimaKosuke DokiMasato HommaBryan J Mathis Tsumugi JonoTomoki OgataKosuke TanakaYuki KasaiMichihiro IwakiAkiko FuyukiAtsushi NakajimaRyuji HayashiTakayuki AndoNaoki IzawaYuko KobayashiYoshiki HorieTatsuya Morita

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)

Naldemedine prevented constipation and improved constipation-related QOL, with possible preventive effect on OINV in patients with cancer starting regularly dosed opioids therapy.

Keyphrases

double blind
placebo controlled
irritable bowel syndrome
clinical trial
chronic pain
pain management
phase iii
phase ii
study protocol
high glucose
diabetic rats
endothelial cells
open label
abdominal pain
randomized controlled trial
cross sectional
oxidative stress